Investment analysts at StockNews.com started coverage on shares of Global Cord Blood (NYSE:CO - Get Free Report) in a research note issued to investors on Saturday. The brokerage set a "strong-buy" rating on the medical research company's stock.
Global Cord Blood Trading Down 47.6%
Global Cord Blood stock traded down $0.50 during mid-day trading on Friday, reaching $0.55. The company had a trading volume of 51,909 shares, compared to its average volume of 216,519. The business has a fifty day simple moving average of $0.94 and a 200 day simple moving average of $1.07. The company has a market cap of $66.86 million, a P/E ratio of 0.86 and a beta of 0.16. Global Cord Blood has a fifty-two week low of $2.03 and a fifty-two week high of $5.50.
About Global Cord Blood
(
Get Free Report)
Global Cord Blood operates as a holding company, which engages in the provision of cord blood banking services. It provides cord blood processing and storage service. The company also offers cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services. The firm preserves cord blood units donated by the public and provides matching services on such donated units and deliver matching units to patients in need of transplants.
Read More
Before you consider Global Cord Blood, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Global Cord Blood wasn't on the list.
While Global Cord Blood currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
